上皮腫治療の世界市場レポート 2025年

上皮腫治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.8％で76億2,000万米ドルに成長します。予測期間中に予想される成長は、標的療法の使用拡大、免疫療法研究の進展、低侵襲治療への嗜好の高まり、新興地域全体のヘルスケアインフラの改善、新しい上皮腫治療薬の規制当局による承認によってもたらされます。この期間に予想される主な動向には、個別化医療の進展、皮膚がん診断におけるAIの採用、併用療法の適用拡大、新規治療法の臨床試験の増加、非侵襲的治療法へのシフトの増加などがあります。

皮膚がんの罹患率の増加は、上皮腫治療市場の成長を促進すると予想されます。皮膚がんは、異常な皮膚細胞の制御不能な増殖を伴いますが、その典型的な原因は、修復されないDNA損傷による突然変異です。皮膚がん患者の増加の主な要因は、オゾン層の破壊などの環境問題とともに、太陽光や日焼けベッドからの紫外線への曝露の増加です。上皮腫の治療は、がん化した上皮細胞を除去することを目的としており、皮膚がんの根本的な原因を効果的にターゲットにしています。例えば、2024年1月、米国がん協会は、2024年に米国で予測される新規メラノーマ症例数は推定10万640人で、男性が約5万9,170人、女性が約4万1,470人であると報告しています。この症例数の増加が、上皮腫治療市場の拡大を後押しする重要な要因となっています。

上皮腫治療市場の主要企業は、治療精度の向上、患者の転帰の改善、個別化医療戦略の支援を目的として、コンパニオン診断薬などの革新的な治療法の開拓を優先しています。コンパニオン診断薬は、安全性と治療効果を最大化し、特定の治療から恩恵を受ける可能性が最も高い患者を特定するために設計された特殊な検査です。例えば、2024年11月、スイスに本社を置く製薬会社ロシュ・ホールディングスAGは、PATHWAY 抗-HER2/neu（4B5）ウサギモノクローナル一次抗体検査の用途拡大についてFDAの承認を取得しました。この承認により、ジヘラ（一般名：zanidatamab-hrii）による治療の対象となり得る、治療歴のある切除不能または転移性のHER2陽性胆道がん（BTC）患者を同定することが可能になります。ロシュの目標は、BTCにおける標的治療の決定を導く信頼性の高い診断ツールを提供することにより、個別化ヘルスケアを推進することです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場 - 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界上皮腫治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の上皮腫治療市場：成長率分析
• 世界の上皮腫治療市場の実績：規模と成長、2019～2024年
• 世界の上皮腫治療市場の予測：規模と成長、2024～2029年、2034年
• 世界上皮腫治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の上皮腫治療市場：疾患タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 基底細胞上皮腫
• 扁平上皮腫
• 悪性上皮腫
• 世界の上皮腫治療市場：治療の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 薬物クラス
• 外科的治療
• 放射線治療
• 光線力学療法
• 併用療法
• 世界の上皮腫治療市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• eコマース
• その他の流通チャネル
• 世界の上皮腫治療市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• 外来手術センター
• 調査・学術機関
• 世界の上皮腫治療市場：基底細胞上皮腫の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 浅部基底細胞上皮腫
• 結節性基底細胞上皮腫
• 浸潤性基底細胞上皮腫
• 硬化性基底細胞上皮腫
• 色素性基底細胞上皮腫
• 世界の上皮腫治療市場：扁平上皮腫の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 皮膚扁平上皮がん
• 口腔扁平上皮がん
• 食道扁平上皮がん
• 肺扁平上皮がん
• 子宮頸部扁平上皮がん
• 世界の上皮腫治療市場：悪性上皮腫の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 類上皮肉腫
• 明細胞肉腫
• 紡錘細胞がん
• 腺様嚢胞がん
• 粘表皮がん

第7章 地域別・国別分析

• 世界の上皮腫治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の上皮腫治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 上皮腫治療市場：競合情勢
• 上皮腫治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co., Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.
• Zhejiang Hisun Pharmaceutical Co. Ltd.
• Verrica Pharmaceuticals Inc.
• Sirnaomics Inc.
• MediWound Ltd
• Philogen SpA
• PellePharm, Inc.
• Kintor Pharmaceutical Limited
• DermBiont
• Transgene SA
• AiViva BioPharma Inc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 上皮腫治療市場2029：新たな機会を提供する国
• 上皮腫治療市場2029：新たな機会を提供するセグメント
• 上皮腫治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Epithelioma treatment refers to medical interventions aimed at managing epithelioma, a tumor that develops from epithelial cells covering various surfaces and organs of the body. Treatment options include tumor removal through surgery, radiation therapy to target malignant cells, and chemotherapy for more advanced or widespread cases. The choice of treatment depends on the tumor's type, stage, and location, as well as the patient's overall health and preferences.

The primary types of epithelioma requiring treatment are basal cell epithelioma, squamous cell epithelioma, and malignant epithelioma. Basal cell epithelioma is a slow-growing tumor of the skin that originates from the basal cells in the epidermis. Treatment methods for this condition include drug therapies, surgery, radiation therapy, photodynamic therapy, and combination treatments. These therapies are distributed through hospital pharmacies, retail pharmacies, e-commerce platforms, and other channels. The treatments are most commonly used in hospitals, specialty clinics, ambulatory surgical centers, and academic or research institutions.

The epithelioma treatment market research report is one of a series of new reports from The Business Research Company that provides epithelioma treatment market statistics, including the epithelioma treatment industry global market size, regional shares, competitors with the epithelioma treatment market share, detailed epithelioma treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the epithelioma treatment industry. This epithelioma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The epithelioma treatment market size has grown rapidly in recent years. It will grow from $4.76 billion in 2024 to $5.24 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. The growth observed during the historic period can be attributed to the rising number of epithelioma cases, progress in radiation therapy, increased reliance on surgical procedures, heightened awareness of skin cancer, and the development of chemotherapy treatments.

The epithelioma treatment market size is expected to see strong growth in the next few years. It will grow to $7.62 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The anticipated growth in the forecast period is driven by the expanding use of targeted therapies, advancements in immunotherapy research, increasing preference for minimally invasive procedures, improvements in healthcare infrastructure across emerging regions, and regulatory approvals for new epithelioma medications. Key trends expected in this period include the advancement of personalized medicine, adoption of AI in skin cancer diagnostics, growing application of combination therapies, a rise in clinical trials for novel treatment methods, and an increasing shift toward non-invasive treatment options.

The increasing incidence of skin cancers is expected to drive the growth of the epithelioma treatment market. Skin cancer involves the uncontrolled growth of abnormal skin cells, typically resulting from unrepaired DNA damage that causes mutations. A major contributing factor to the rise in skin cancer cases is increased exposure to ultraviolet radiation from sunlight and tanning beds, along with environmental issues such as ozone layer depletion. Epithelioma treatments aim to eliminate cancerous epithelial cells, effectively targeting the underlying cause of skin cancer. For example, in January 2024, the American Cancer Society reported an estimated 100,640 new melanoma cases projected in the U.S. for 2024, with about 59,170 in men and 41,470 in women. This growing number of cases is a key factor fueling the expansion of the epithelioma treatment market.

Leading companies in the epithelioma treatment market are prioritizing the development of innovative therapies, such as companion diagnostics, to improve treatment accuracy, enhance patient outcomes, and support personalized medicine strategies. Companion diagnostics are specialized tests designed to identify patients who are most likely to benefit from specific treatments, maximizing safety and therapeutic effectiveness. For instance, in November 2024, Roche Holdings AG, a pharmaceutical company based in Switzerland, received FDA approval for an expanded use of its PATHWAY anti-HER2/neu (4B5) rabbit monoclonal primary antibody test. This approval enables the test to identify patients with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with Ziihera (zanidatamab-hrii). Roche's goal is to advance personalized healthcare by offering a reliable diagnostic tool to guide targeted therapy decisions in BTC.

In August 2022, Ipsen SA, a biopharmaceutical company headquartered in France, acquired Epizyme Inc. to expand its oncology portfolio. This acquisition grants Ipsen access to Epizyme's innovative cancer treatments, including its lead EZH2 inhibitor, Tazverik. Epizyme Inc. is a U.S.-based biopharmaceutical firm specializing in epithelioma treatment.

Major players in the epithelioma treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sanofi, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Verrica Pharmaceuticals Inc., Sirnaomics Inc., MediWound Ltd, Philogen SpA, PellePharm, Inc., Kintor Pharmaceutical Limited, DermBiont, Transgene SA, AiViva BioPharma Inc.

North America was the largest region in the epithelioma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in epithelioma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the epithelioma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The epithelioma treatment market consists of revenues earned by entities providing services such as radiation therapy, chemotherapy, and targeted therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The epithelioma treatment market also includes sales of pharmaceuticals, immunotherapy drugs, and advanced treatment modalities designed to improve patient outcomes and reduce the risk of recurrence or metastasis. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Epithelioma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on epithelioma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for epithelioma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The epithelioma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Basal Cell Epithelioma; Squamous Cell Epithelioma; Malignant Epithelioma
• 2) By Treatment Type: Drug Class; Surgical Treatments; Radiation Therapy; Photodynamic Therapy; Combination Therapies
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; E-Commerce; Other Distribution Channels
• 4) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Research And Academic Institutes
• Subsegments:
• 1) By Basal Cell Epithelioma: Superficial Basal Cell Epithelioma; Nodular Basal Cell Epithelioma; Infiltrative Basal Cell Epithelioma; Morpheaform (Sclerosing) Basal Cell Epithelioma; Pigmented Basal Cell Epithelioma
• 2) By Squamous Cell Epithelioma: Cutaneous Squamous Cell Carcinoma; Oral Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma; Pulmonary Squamous Cell Carcinoma; Cervical Squamous Cell Carcinoma
• 3) By Malignant Epithelioma: Epithelioid Sarcoma; Clear Cell Sarcoma; Spindle Cell Carcinoma; Adenoid Cystic Carcinoma; Mucoepidermoid Carcinoma
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Sanofi; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Epithelioma Treatment Market Characteristics

3. Epithelioma Treatment Market Trends And Strategies

4. Epithelioma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Epithelioma Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Epithelioma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Epithelioma Treatment Market Growth Rate Analysis
• 5.4. Global Epithelioma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Epithelioma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Epithelioma Treatment Total Addressable Market (TAM)

6. Epithelioma Treatment Market Segmentation

• 6.1. Global Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Basal Cell Epithelioma
• Squamous Cell Epithelioma
• Malignant Epithelioma
• 6.2. Global Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug Class
• Surgical Treatments
• Radiation Therapy
• Photodynamic Therapy
• Combination Therapies
• 6.3. Global Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce
• Other Distribution Channels
• 6.4. Global Epithelioma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Research And Academic Institutes
• 6.5. Global Epithelioma Treatment Market, Sub-Segmentation Of Basal Cell Epithelioma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Superficial Basal Cell Epithelioma
• Nodular Basal Cell Epithelioma
• Infiltrative Basal Cell Epithelioma
• Morpheaform (Sclerosing) Basal Cell Epithelioma
• Pigmented Basal Cell Epithelioma
• 6.6. Global Epithelioma Treatment Market, Sub-Segmentation Of Squamous Cell Epithelioma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cutaneous Squamous Cell Carcinoma
• Oral Squamous Cell Carcinoma
• Esophageal Squamous Cell Carcinoma
• Pulmonary Squamous Cell Carcinoma
• Cervical Squamous Cell Carcinoma
• 6.7. Global Epithelioma Treatment Market, Sub-Segmentation Of Malignant Epithelioma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epithelioid Sarcoma
• Clear Cell Sarcoma
• Spindle Cell Carcinoma
• Adenoid Cystic Carcinoma
• Mucoepidermoid Carcinoma

7. Epithelioma Treatment Market Regional And Country Analysis

• 7.1. Global Epithelioma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Epithelioma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Epithelioma Treatment Market

• 8.1. Asia-Pacific Epithelioma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Epithelioma Treatment Market

• 9.1. China Epithelioma Treatment Market Overview
• 9.2. China Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Epithelioma Treatment Market

• 10.1. India Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Epithelioma Treatment Market

• 11.1. Japan Epithelioma Treatment Market Overview
• 11.2. Japan Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Epithelioma Treatment Market

• 12.1. Australia Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Epithelioma Treatment Market

• 13.1. Indonesia Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Epithelioma Treatment Market

• 14.1. South Korea Epithelioma Treatment Market Overview
• 14.2. South Korea Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Epithelioma Treatment Market

• 15.1. Western Europe Epithelioma Treatment Market Overview
• 15.2. Western Europe Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Epithelioma Treatment Market

• 16.1. UK Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Epithelioma Treatment Market

• 17.1. Germany Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Epithelioma Treatment Market

• 18.1. France Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Epithelioma Treatment Market

• 19.1. Italy Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Epithelioma Treatment Market

• 20.1. Spain Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Epithelioma Treatment Market

• 21.1. Eastern Europe Epithelioma Treatment Market Overview
• 21.2. Eastern Europe Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Epithelioma Treatment Market

• 22.1. Russia Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Epithelioma Treatment Market

• 23.1. North America Epithelioma Treatment Market Overview
• 23.2. North America Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Epithelioma Treatment Market

• 24.1. USA Epithelioma Treatment Market Overview
• 24.2. USA Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Epithelioma Treatment Market

• 25.1. Canada Epithelioma Treatment Market Overview
• 25.2. Canada Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Epithelioma Treatment Market

• 26.1. South America Epithelioma Treatment Market Overview
• 26.2. South America Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Epithelioma Treatment Market

• 27.1. Brazil Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Epithelioma Treatment Market

• 28.1. Middle East Epithelioma Treatment Market Overview
• 28.2. Middle East Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Epithelioma Treatment Market

• 29.1. Africa Epithelioma Treatment Market Overview
• 29.2. Africa Epithelioma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Epithelioma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Epithelioma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Epithelioma Treatment Market Competitive Landscape And Company Profiles

• 30.1. Epithelioma Treatment Market Competitive Landscape
• 30.2. Epithelioma Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co., Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Epithelioma Treatment Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Eli Lilly and Company
• 31.3. Amgen Inc.
• 31.4. Regeneron Pharmaceuticals Inc.
• 31.5. Sun Pharmaceutical Industries Ltd.
• 31.6. Zhejiang Hisun Pharmaceutical Co. Ltd.
• 31.7. Verrica Pharmaceuticals Inc.
• 31.8. Sirnaomics Inc.
• 31.9. MediWound Ltd
• 31.10. Philogen SpA
• 31.11. PellePharm, Inc.
• 31.12. Kintor Pharmaceutical Limited
• 31.13. DermBiont
• 31.14. Transgene SA
• 31.15. AiViva BioPharma Inc

32. Global Epithelioma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Epithelioma Treatment Market

34. Recent Developments In The Epithelioma Treatment Market

35. Epithelioma Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Epithelioma Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Epithelioma Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Epithelioma Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer